Long-Term Soliris Treatment Improves Kidney Function Long-Term Soliris Treatment Improves Kidney Function

Long-Term Soliris Treatment Improves Kidney Function

Biotech Business 2010, Jan 1, 23, 1

    • $5.99
    • $5.99

Publisher Description

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The study showed that after 38 weeks of Soliris treatment, all patients with chronic kidney disease (CKD), a clinical consequence of chronic hemolysis, either stabilized or improved. Other studies have shown that kidney disease accounts for 18 percent of deaths among Japanese patients with PNH. (1) In the studied patients, Soliris therapy was also associated with a sustained reduction in hemolysis, which resulted in a further improvement in levels of fatigue, as well as a maintained improvement in anemia and a reduction in transfusion requirements. The data were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in a poster titled "Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study."

GENRE
Business & Personal Finance
RELEASED
2010
January 1
LANGUAGE
EN
English
LENGTH
5
Pages
PUBLISHER
Worldwide Videotex
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
53.4
KB
Alexion's Soliris Gets 2008 Prix Galien USA Award Alexion's Soliris Gets 2008 Prix Galien USA Award
2008
Impact of Single-Needle Therapy in New Chronic Hemodialysis Starts for Individuals with Arteriovenous Fistulae (Report) Impact of Single-Needle Therapy in New Chronic Hemodialysis Starts for Individuals with Arteriovenous Fistulae (Report)
2009
What's the Buzz?(Pharmacy News and Reviews) What's the Buzz?(Pharmacy News and Reviews)
2007
Cyclacel Reports Phase 2 Survival Data with Sapacitabine Cyclacel Reports Phase 2 Survival Data with Sapacitabine
2011
The Use of Alternative Anti-Coagulation Strategies for a Nocturnal Home Hemodialysis Patient with Heparin-Induced Thrombocytopenia (Clinical Report) The Use of Alternative Anti-Coagulation Strategies for a Nocturnal Home Hemodialysis Patient with Heparin-Induced Thrombocytopenia (Clinical Report)
2008
Agennix AG Gets Positive Results from Talactoferrin Trial Agennix AG Gets Positive Results from Talactoferrin Trial
2010
Antidepressants/Cocaine Interact with Brain Cell Targets Antidepressants/Cocaine Interact with Brain Cell Targets
2008
Tovaxin Reduces Disability for Multiple Scelerosis (Clinical Report) Tovaxin Reduces Disability for Multiple Scelerosis (Clinical Report)
2008
Millennium/Harvard Medical School Sign Cancer Research Pact Millennium/Harvard Medical School Sign Cancer Research Pact
2008
Alexion's Soliris Gets 2008 Prix Galien USA Award Alexion's Soliris Gets 2008 Prix Galien USA Award
2008
Chelsea Reports Preliminary Phase III Droxidopa Data (Clinical Report) Chelsea Reports Preliminary Phase III Droxidopa Data (Clinical Report)
2009
Smart Chip System Used to Evaluate Homspera in Wound Healing Studies Smart Chip System Used to Evaluate Homspera in Wound Healing Studies
2009